Mitsubishi Tanabe buys up NeuroDerm in $1.1B deal

The deal will be the largest ever purchase of an Israeli firm by a Japanese company.

Mitsubishi Tanabe is to spend $1.1 billion on Parkinson’s disease biotech NeuroDerm as it looks to boost its U.S. presence and CNS pipeline.

The deal comes several months after the Japanese drugmaker gained an FDA approval for ALS med Radicava, which got approvals in Asia back in 2015.

For its $1.1 billion, or $39 a share (a 17% premium on Friday’s close), Mitsubishi Tanabe gets its hands on NeuroDerm’s lead product, ND0612, which works as a combination of the two Parkinson’s drugs that control symptoms of the disease by replacing reduced dopamine in the brain.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It’s not been easy sailing for the Israeli company, however. A few years back, it was hit was an FDA clinical hold for the Parkinson’s therapy, but this was later lifted.

ND0612 is currently in late-stage testing, and the biotech believes it could gain U.S. approval by 2019 and reach peak sales of around $1.7 billion.

RELATED: NeuroDerm stock up as FDA lifts hold on its subcutaneously delivered Parkinson's candidate

NeuroDerm said in the brief statement that the deal should close by Q4.

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said Oded Lieberman, Ph.D., CEO of NeuroDerm.

Mitsubishi Tanabe "has demonstrated development and commercialization expertise in the field of neurology and we are confident that the combination of their resources and the robust data supporting ND0612, our Phase III Parkinson’s disease product candidate, will help make this important new therapy available as broadly and rapidly as possible.

“The transaction also provides our shareholders with a significant return on their investment in NeuroDerm, reflecting the value that we have created with our pipeline and technologies,” Lieberman said.

As Reuters points out, the deal will be the largest ever purchase of an Israeli firm by a Japanese company.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.